CANA 300 mg (N = 367)

7.9 ± 0.9

−0.88 ± 0.05

−0.15

(−0.27, −0.03)

FPG (mg/dL) at 52 Weeks

Baseline Mean ± SD

LS Mean Change ± SE

Difference vs. SITA

(95% CI)

SITA 100 mg

(N = 366)

167.6 ± 41.4

−18.0 ± 1.8

-

CANA 100 mg (N = 368)

169.4 ± 41.4

−27.0 ± 1.8

−9.0^*

(−12.6, −3.6)

CANA 300 mg (N = 367)

173.0 ± 45.0

−36.0 ± 1.8

−18.0^*

(−21.6, −12.6)

^*p < 0.001 vs. SITA

Body Weight (kg) at 52 Weeks

Baseline Mean ± SD

LS Mean Percent Change ± SE

Difference vs. SITA

(95% CI)

SITA 100 mg

(N = 355)

87.7 ± 21.6

−1.3 ± 0.2

-

CANA 100 mg (N = 365)

88.8 ± 22.2

−3.8 ± 0.2

−2.4^*

(−3.0, −1.8)

CANA 300 mg (N = 360)

85.4 ± 20.9

−4.2 ± 0.2

−2.9^*

(−3.4, −2.3)

^*p < 0.001 vs. SITA

Schernthaner

(2013)

Randomized

Double-blind

Active-

controlled

755 T2DM

(422M; 333F)

MET and SU Adjustment Period (if applicable): up to 12 weeks

(Including an 8-week dose-stable period)

Single-blind, Placebo Run-in Period: 2 weeks

Double-blind

Treatment Period: 52 weeks

Group A: SITA 100 mg daily

Group B: CANA 300 mg daily

Follow-up Period: 4 weeks

HbA1C (%) at 52 Weeks

Baseline Mean ± SD

LS Mean Change

Difference vs. SITA

(95% CI)

SITA 100 mg

(N = 378)

8.1 ± 0.9

−0.66

-

CANA 300 mg (N = 377)

8.1 ± 0.9

−1.03

−0.37

(−0.50, −0.25)

FPG (mg/dL) at 52 Weeks

Baseline Mean

LS Mean Change

Difference vs. SITA

SITA 100 mg

(N = 378)

165.8 ± 44.9

−5.9

-

CANA 300 mg (N = 377)

169.4 ± 42.4

−29.9

−24.1^*

^*p < 0.001 vs. SITA

Body Weight (kg) at 52 Weeks

Baseline Mean

LS Mean Percent Change

Difference vs. SITA

(95% CI)

SITA

(N = 378)

89.1 ± 23.2

0.3

-

CANA 300 mg (N = 377)

87.4 ± 23.2

−2.5

−2.8^*

^*p < 0.001 vs. SITA